LY2228820 is a selective inhibitor of the p38 mitogen-activated protein kinase (MAPK) pathway, which plays a key role in inflammation and stress responses. It has been investigated primarily for its potential in cancer therapy, especially in enhancing the effectiveness of chemotherapy and radiation by modulating tumor microenvironment signaling. The compound helps suppress cytokine production that can promote tumor growth and resistance to treatment. It has shown promise in preclinical models for improving outcomes in cancers such as ovarian and breast cancer. Additionally, LY2228820 is used as a research tool to study inflammatory pathways and cellular responses to stress, supporting drug development efforts targeting inflammatory and oncogenic processes.